Genzyme to resubmit Lemtrada marketing application to FDA
FDA after consultations with the Genzyme has asked it to modify the data sets presentation to enable the agency to process the application. The FDA has not requested
Novartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies.
Three month, multi-site, double blind, randomized, placebo-controlled, parallel-group trial is designed to assess the safety, tolerability and potential effect of anatabine in subjects with Alzheimer’s disease. Previous tissue